Omega Fatty Acid Levels and Your Genetics

Written by Scott Peeples, BS Biomedical Sciences · ExomeDNA Founder Reviewed by ExomeDNA Editorial Process · /methodology/editorial-process Last reviewed: 2026-05-29

This page contains general information only. For health decisions, consult a clinician.

Omega Fatty Acid Levels is a measure of circulating polyunsaturated fats — including omega-3s (EPA and DHA) and omega-6s (linoleic acid and arachidonic acid) — that varies substantially between individuals based on diet and genetics. Studies have linked variants near the APOA5 gene to meaningful differences in how efficiently the body clears triglyceride-rich particles carrying omega fatty acids from the bloodstream.^[1] Below: how your genetics shapes omega fatty acid metabolism, the key genes involved, and what the research currently supports.

What is omega fatty acid levels?

Omega fatty acid levels refers to the concentration of long-chain polyunsaturated fats circulating in plasma. These fats fall into two main families: omega-3s (alpha-linolenic acid, EPA, DHA) and omega-6s (linoleic acid, arachidonic acid). The balance between these families — rather than any single number — is what researchers most consistently link to downstream effects on inflammation, membrane composition, and lipid metabolism. Genetics influences both how efficiently dietary omega fats are absorbed from the gut and how rapidly they are cleared from the bloodstream once absorbed.

The genetics behind omega fatty acid levels

Several genes with distinct biological roles converge on omega fatty acid metabolism. Understanding each one clarifies a different step in the pathway from dietary fat to circulating level.

APOA5 and lipoprotein lipase activation

Apolipoprotein A5 (APOA5) is a small protein produced by the liver that plays a pivotal role in clearing triglyceride-rich lipoproteins — the particles that carry omega fatty acids in circulation. APOA5 works by activating lipoprotein lipase (LPL), the enzyme that breaks triglycerides down into free fatty acids at the capillary wall. It does this partly by displacing apolipoprotein C-III (APOC-III), a natural inhibitor of LPL. The practical consequence: individuals with APOA5 variants that reduce LPL activation efficiency tend to clear omega-3-containing particles more slowly, which can blunt the triglyceride-lowering effect of fish oil supplementation. APOA5 is one of the strongest single-gene determinants of plasma triglyceride levels, and the omega-3 response varies meaningfully by genotype at this locus.

ABCB11 and bile acid-dependent absorption

ABCB11, known as the bile salt export pump (BSEP), sits on the canalicular membrane of liver cells and drives bile acids into the bile duct using ATP. Bile acids secreted into the small intestine are essential for solubilizing dietary fats — including omega-3 and omega-6 fatty acids — into micelles that intestinal cells can absorb. Variants in ABCB11 that alter bile secretion rate therefore influence how efficiently a meal rich in fatty fish or omega-3-fortified foods actually delivers those fats to the bloodstream. Severe ABCB11 mutations cause progressive familial intrahepatic cholestasis; common variants create subtler shifts in bile acid flux that may affect fat absorption efficiency.

AGO2 and microRNA-mediated metabolic regulation

Argonaute 2 (AGO2) is the catalytic engine of the RNA-induced silencing complex (RISC) — the molecular machinery that uses microRNAs (miRNAs) to silence specific messenger RNA targets. This mechanism is a major post-transcriptional control layer for metabolic gene expression. Several well-characterized miRNAs — including miR-33, miR-122, and miR-27 — regulate genes involved in fatty acid synthesis, beta-oxidation, and lipoprotein assembly by guiding AGO2 to silence their mRNA. AGO2 variants that alter miRNA-mediated regulation may shift how the liver adjusts fatty acid production and oxidation in response to incoming dietary omega fats, adding a layer of gene-expression control on top of the direct enzymatic pathways.

ABCA1 and HDL biogenesis

ABCA1 (ATP-binding cassette transporter A1) mediates cholesterol efflux from cells to lipid-poor apolipoprotein A-I, the first step in HDL particle formation. Fatty acid metabolism and HDL biogenesis are co-regulated: ABCA1 expression is itself subject to nuclear receptor signaling pathways that respond to lipid load. Variants in ABCA1 that reduce cholesterol efflux are associated with lower HDL levels and have downstream effects on lipoprotein composition, including how omega fatty acids are packaged and transported.

APOB — the lipoprotein carrier protein

APOB is the structural protein of VLDL and LDL particles, the vehicles that transport newly synthesized lipids — including esterified omega fatty acids — out of the liver. APOB is required for LDL particle assembly and secretion; variants that alter APOB production or structure influence plasma LDL levels and the efficiency with which the liver exports fatty acids into circulation.

ALDH1A2 — retinoic acid and lipid metabolic overlap

Aldehyde dehydrogenase 1A2 (ALDH1A2) catalyzes the synthesis of retinoic acid from retinaldehyde. Retinoic acid is a potent regulator of multiple lipid metabolism genes, operating through retinoic acid receptors (RARs) that share ligand-binding crosstalk with peroxisome proliferator-activated receptors (PPARs) — the same nuclear receptor family central to fatty acid oxidation and omega-3 sensing. ALDH1A2 variants affecting retinoic acid synthesis therefore influence the transcriptional environment governing omega fatty acid processing.

Large-scale Mendelian randomization using genetically-predicted lipid levels across UK Biobank participants has characterized how omega fatty acid-relevant loci associate with downstream metabolomic signatures, providing evidence that common variants at APOA5 and related genes influence circulating lipid profiles beyond what diet alone explains.^[1]

What the research says

Research base: Robust. Genome-wide studies of omega fatty acid levels benefit from large biobank cohorts and precise nuclear magnetic resonance (NMR) metabolomics platforms that can simultaneously measure hundreds of lipid species. This has enabled well-powered discovery and replication of loci influencing circulating omega fatty acid levels.

A 2022 study by Richardson and colleagues applied Mendelian randomization — a genetic epidemiology method that uses inherited variants as natural experiments — to characterize metabolomic signatures of lipid-modifying pathways across large UK Biobank samples.^[1] This approach helped disentangle genetic from dietary contributions to circulating omega fatty acid levels and identified specific gene regions where variants consistently track with omega lipid profiles.

The field benefits from the convergence of genomic discovery (identifying which variants matter), functional biology (understanding the APOA5/LPL/APOC-III regulatory axis), and dietary intervention trials (showing that fish oil response varies by genotype). Taken together, the evidence picture for omega fatty acid genetics is well-developed, though specific effect sizes for individual variants depend on the population studied and the specific omega fatty acid measured.

For a detailed explanation of how ExomeDNA interprets this evidence, see the ExomeDNA methodology page.

Omega-3 triglyceride response varies by genotype — APOA5 variants that affect lipoprotein lipase activation efficiency are among the strongest common genetic determinants of how much plasma triglycerides fall in response to omega-3 supplementation, illustrating why the same fish oil dose produces different outcomes across individuals.^[1]

How omega fatty acid levels affect you

Circulating omega fatty acid levels sit at the intersection of diet, genetics, and metabolic health. For most people, omega-3s (EPA and DHA) are considered broadly beneficial: they serve as precursors to anti-inflammatory eicosanoids, are incorporated into cell membranes where they influence fluidity and receptor function, and are reliably associated with lower plasma triglycerides in intervention studies. Omega-6 fatty acids — particularly linoleic acid — are essential but their balance relative to omega-3s matters: modern Western diets tend toward high omega-6 intake, and the omega-6 to omega-3 ratio influences inflammatory signaling.

Genetics adds a layer of individual variation on top of diet. Two people eating the same amount of fatty fish may end up with meaningfully different circulating EPA and DHA levels if their APOA5 variants differ in LPL activation efficiency, or if their ABCB11 variants affect bile acid secretion and therefore intestinal absorption. This helps explain why population-level dietary recommendations — which are built on averages — may not fully predict an individual's response to omega-3 supplementation.

The AGO2/miRNA layer means that gene expression responses to omega-3 intake also vary: when omega-3 fatty acids enter the liver and bind PPAR receptors, the downstream transcriptional response includes changes in miRNA profiles, and the efficiency of AGO2-mediated mRNA silencing then determines how far that signal propagates through fatty acid synthesis and oxidation gene networks.

Working with your omega fatty acid result

Understanding your result means thinking about both the level and the pathway. The following steps are grounded in the metabolic biology above:

1. Prioritize fatty fish over supplements as a first step. Salmon, mackerel, sardines, and herring provide EPA and DHA alongside natural co-factors (phospholipids, vitamin D, astaxanthin) that may aid absorption and bioavailability beyond what refined fish oil capsules deliver. Two to three servings per week is the commonly cited threshold in dietary guidance.
2. If you supplement with fish oil, monitor your triglyceride response. Because APOA5 variants affect how efficiently LPL is activated, triglyceride-lowering from fish oil supplementation varies by genotype.^[1] A lipid panel 2-3 months after starting or increasing omega-3 supplementation gives objective data on your individual response.
3. Consider higher omega-3 doses if your triglycerides remain elevated despite supplementation. Prescription-strength omega-3 formulations (icosapentaenoic acid EPA; combined EPA/DHA) are used at 2-4 grams per day in lipid management contexts. Discuss dosing with a clinician who can interpret your lipid panel in context.
4. Adopt a Mediterranean-style eating pattern. The Mediterranean diet consistently shows favorable effects on both omega fatty acid profiles and cardiovascular biomarkers. It emphasizes olive oil, fatty fish, legumes, vegetables, and nuts — naturally shifting the omega-6/omega-3 ratio and improving the lipid milieu in which APOA5 and ABCB11 variants operate.
5. Reduce processed foods high in omega-6-rich seed oils. Corn, soybean, and sunflower oils are high in linoleic acid (omega-6). Reducing these while increasing omega-3 sources improves the ratio independent of genetics.
6. Track triglycerides, not just omega-3 intake. Triglycerides are the most consistently measurable downstream biomarker of omega-3 status and APOA5/LPL axis efficiency. A fasting triglyceride level on a standard metabolic panel is the most accessible way to gauge whether your genetic and dietary inputs are producing a favorable metabolic environment.

Related traits and genes

Sibling traits in Nutrition and Metabolism:

• Polyunsaturated Fatty Acid Levels: FADS1, FADS2, and Conversion Genetics — See how the FADS1 and FADS2 desaturase enzymes convert short-chain plant omega-3s into EPA and DHA, a distinct upstream step from the clearance pathways covered on this page.

Cross-category traits sharing genes or mechanisms:

• High Triglycerides Genetic Risk: APOA5, LPL, and GCKR — APOA5 is the key shared gene; see how its role in LPL activation connects omega fatty acid clearance to the broader triglyceride landscape.
• DHA Omega-3 Genetics: FADS2, APOE, and Synthesis Loci — DHA is the most biologically active omega-3 fatty acid; this page covers the specific genetic loci influencing DHA levels in circulation.

Frequently asked questions

Can my genetics predict how I will respond to fish oil supplementation?

Genetics influences fish oil response but does not fully determine it. Variants in the APOA5 gene affect how efficiently lipoprotein lipase (LPL) is activated, which changes how rapidly triglyceride-rich particles carrying omega fatty acids are cleared from the blood. People with APOA5 variants linked to lower LPL activation efficiency may see smaller triglyceride drops in response to fish oil than those with more favorable variants. Monitoring triglycerides before and 2-3 months after starting supplementation gives the most useful individual data.

What is the difference between omega-3 and omega-6 fatty acids?

Both are polyunsaturated fatty acids (PUFAs) that the body cannot synthesize from scratch and must obtain from diet. Omega-3 fatty acids — particularly EPA and DHA found in fatty fish — serve as precursors to anti-inflammatory signaling molecules and support membrane function in brain and heart tissue. Omega-6 fatty acids — particularly linoleic acid in plant oils — are also essential, but in large amounts relative to omega-3, they favor pro-inflammatory signaling pathways. Genetics influences circulating levels of both families; the balance between them is what most research focuses on for metabolic outcomes.

How does the ABCB11 gene affect my omega fatty acid levels?

ABCB11 encodes the bile salt export pump, which moves bile acids from liver cells into the bile duct. Bile acids are necessary for emulsifying dietary fats — including omega fatty acids — into small droplets (micelles) that intestinal cells can absorb. If ABCB11 variants reduce bile secretion, dietary omega fats may be absorbed less efficiently, meaning that the amount of EPA and DHA reaching the bloodstream from a given meal could be lower than in someone with fully functional ABCB11. Severe ABCB11 dysfunction causes progressive familial intrahepatic cholestasis; milder variants produce subtler shifts in fat absorption.

What role does AGO2 play in fatty acid metabolism?

AGO2 (Argonaute 2) is the protein at the core of the RNA-induced silencing complex, the molecular machine that uses microRNAs to silence specific genes after they have been transcribed. Several microRNAs (including miR-33, miR-122, and miR-27) regulate genes involved in fatty acid synthesis, breakdown, and lipoprotein assembly. By controlling how efficiently these microRNAs silence their target genes, AGO2 variants can shift the balance of how the liver adjusts fatty acid production and oxidation — particularly in response to incoming dietary omega fats activating PPAR receptors.

Is a higher omega-3 level always better?

Omega-3 fatty acids are broadly beneficial within the range seen in healthy populations, but the relationship is not a simple linear one where higher is always better. The research most consistently supports adequate omega-3 intake for favorable triglyceride and inflammatory profiles. Very high omega-3 supplementation beyond established doses carries potential considerations around bleeding time and oxidized lipid formation. The genetics covered on this page helps explain why individual responses vary, but the practical target for most people is ensuring adequate intake through diet plus supplementation if needed, not maximizing absolute levels.

Should I get a specific omega-3 blood test alongside my genetic results?

A specific plasma phospholipid omega-3 index or NMR lipoprotein panel provides direct measurement of your circulating omega-3 status — information your genetic result alone cannot give. Genetics tells you about predispositions in the absorption and clearance pathways; a blood test tells you where you actually stand today, given your current diet and supplement use. For most people, a standard fasting triglyceride level is the most accessible proxy, with a formal omega-3 index available through specialty labs.

References

1. Richardson TG et al. Characterising metabolomic signatures of lipid-modifying therapies through drug target Mendelian randomisation. PLOS Genetics. 2022. PMID: 35213538.

Data sources:

• GWAS Catalog (NHGRI-EBI, accessed 2026-05-29)
• Open Targets Platform (CC0 1.0, accessed 2026-05-29)
• ClinVar (NCBI, accessed 2026-05-29) — entries at ≥2-star review status
• ClinGen Gene-Disease Validity (CC0 1.0, accessed 2026-05-29)

ExomeDNA genetic results are for wellness and educational purposes only. Consult a clinician for personalized health guidance.